Euan Alexander Fraser Fordyce

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Respivert Limited, Pulmocide Limited, Cancer Research Technology Limited. Active years: 2016-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Euan Alexander Fraser Fordyce. Retrieved from https://idiyas.com/inventor/euan-alexander-fraser-fordyce

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 95.0

CIPO Patents = 4

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 6.8

ph-index = 3

Forward Citations = 57(Granted Patents)

Location History:

Nottinghamshire, GB (2018)
Nottingham, GB (2016 - 2023)

Company Filing History:

Cancer Research Technology Limited

patents

4. 3 out of 26

Topivert Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2016-2023

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

p38 MAP Kinase

RET Kinase

Pyrazolyl-Ureas

Inhibitors

Benzo[b]thieno Derivatives

Compounds

Kinase Inhibitors

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11661423 - Heterocyclic compounds as RET kinase inhibitors (2023-05-30),

2. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

3. 11548896 - Heterocyclic compounds as RET kinase inhibitors (2023-01-10),

4. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

5. 10954241 - Heterocyclic compounds as ret kinase inhibitors (2021-03-23),

6. 10844067 - Heterocyclic compounds as RET kinase inhibitors (2020-11-24),

7. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

8. 10626126 - Compounds (2020-04-21),

9. 10472375 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative (2019-11-12),

10. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

11. 10273249 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative (2019-04-30),

12. 10189863 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives (2019-01-29),

13. 10160772 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives (2018-12-25),

14. 10045980 - Inhibitor of p38 map kinase (2018-08-14),

15. 10035810 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative (2018-07-31),

Title: Euan Alexander Fraser Fordyce: Innovator in Pharmaceutical Patents

Introduction

Euan Alexander Fraser Fordyce is a prolific inventor based in Nottingham, GB, recognized for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 20 patents, he stands at the forefront of developing solutions aimed at treating various diseases, including cancer and inflammatory conditions.

Latest Patents

Among his latest innovations, Fordyce has developed heterocyclic compounds that serve as RET kinase inhibitors. This invention focuses on compounds that effectively inhibit the activity of the RET kinase enzyme, which is implicated in various proliferative disorders. The patent also details the processes for preparing these compounds, their pharmaceutical compositions, and their potential use in treating diseases where RET kinase activity plays a crucial role.

Additionally, he has patented a compound that acts as an inhibitor of p38 MAP kinase. This innovation is particularly relevant in the treatment of inflammatory diseases, offering a promising avenue for therapeutic intervention.

Career Highlights

Throughout his career, Euan Fordyce has been associated with several innovative companies. Notable among them are Respivert Limited and Pulmocide Limited, where he has contributed his expertise in drug development and patenting.

Collaborations

Fordyce has collaborated with esteemed professionals in the field, including Stuart Thomas Onions and John King-Underwood. These partnerships have fostered a creative environment for advancing pharmaceutical research and innovation.

Conclusion

Euan Alexander Fraser Fordyce's extensive work in patenting novel compounds reveals his dedication to enhancing medical treatments. His contributions not only showcase his inventive spirit but also significantly impact the healthcare industry, paving the way for future innovations in pharmacology.

Profile summary based on public USPTO records.